首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3443413篇
  免费   253171篇
  国内免费   6109篇
耳鼻咽喉   47018篇
儿科学   112572篇
妇产科学   93993篇
基础医学   498637篇
口腔科学   98272篇
临床医学   313344篇
内科学   663477篇
皮肤病学   77030篇
神经病学   272240篇
特种医学   129153篇
外国民族医学   693篇
外科学   518238篇
综合类   75978篇
现状与发展   14篇
一般理论   1255篇
预防医学   267068篇
眼科学   82633篇
药学   254717篇
  12篇
中国医学   7546篇
肿瘤学   188803篇
  2021年   26889篇
  2019年   27782篇
  2018年   39057篇
  2017年   29478篇
  2016年   32933篇
  2015年   37185篇
  2014年   52407篇
  2013年   78208篇
  2012年   107874篇
  2011年   114341篇
  2010年   68231篇
  2009年   64009篇
  2008年   106781篇
  2007年   113780篇
  2006年   115047篇
  2005年   111034篇
  2004年   106803篇
  2003年   102387篇
  2002年   98840篇
  2001年   163014篇
  2000年   167347篇
  1999年   140354篇
  1998年   39869篇
  1997年   34854篇
  1996年   35046篇
  1995年   33249篇
  1994年   30572篇
  1993年   28584篇
  1992年   108245篇
  1991年   105206篇
  1990年   101940篇
  1989年   98358篇
  1988年   90198篇
  1987年   88288篇
  1986年   83049篇
  1985年   79481篇
  1984年   59011篇
  1983年   50285篇
  1982年   29364篇
  1979年   53684篇
  1978年   37853篇
  1977年   31787篇
  1976年   30144篇
  1975年   32053篇
  1974年   38828篇
  1973年   37182篇
  1972年   34707篇
  1971年   32633篇
  1970年   30278篇
  1969年   28628篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
11.
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing.  相似文献   
12.
13.
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19.  相似文献   
14.
15.
16.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy  相似文献   
17.
18.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号